AUTL – autolus therapeutics plc - american depositary shares (US:NASDAQ)
Stock Stats
News
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $7.60 price target on the stock, up previously from $7.00.
Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023) [Yahoo! Finance]
Autolus Therapeutics plc (NASDAQ: AUTL) was upgraded by analysts at Redburn Atlantic from a "neutral" rating to a "buy" rating. They now have a $13.00 price target on the stock.
Form SC 13G/A Autolus Therapeutics Filed by: Paradigm Biocapital Advisors LP
Form S-8 Autolus Therapeutics
Form SC 13G/A Autolus Therapeutics Filed by: Syncona Portfolio Ltd
Form SC 13G/A Autolus Therapeutics Filed by: Deep Track Capital, LP
Form 10-Q Autolus Therapeutics For: Sep 30
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.